[Treatment of chronic urticaria with astemizole: a multicenter pediatric study].

Abstract

An open multicentric pediatric clinical trial has been performed to evaluate the safety and efficacy of astemizole (HISMANAL suspension) at a 1 ml (2 mg) dosage per 10 kg body weight once daily in children with chronic urticaria. A good and very good effect has been observed in 63.2% of the children at day 7, in 79.2% after 2 weeks and in 88.9% at the end of the treatment (4 weeks). A marked improvement of the symptoms was reported in 63.8% of children at day 7. There was no decrease of efficacy at the end of the treatment. Tolerance was good in 87.% of the cases. Astemizole seems to be a useful treatment for chronic urticaria in pediatrics.

• Authors: M T Guinnepain
• Journal: Allergie et immunologie (Allerg Immunol (Paris)) Vol. 19 Issue 4 Pg. 173, 175-6 (Apr 1987) ISSN: 0397-9148 [Print] France
• Vernacular Title: Traitement de l'urticaire chronique par l'astémizole: étude multicentrique pédiatrique.
• PMID: 3134034 (Publication Type: English Abstract, Journal Article)

Chemical References

• Benzimidazoles
• Astemizole

Topics

• Adolescent
• Astemizole
• Benzimidazoles (therapeutic use)
• Child
• Child, Preschool
• Chronic Disease
• Cross-Sectional Studies
• Female
• France
• Humans
• Male
• Urticaria (drug therapy, immunology)